Johns Hopkins wins NIH R01 to study GLP-1 long-term value
A research team led by the Johns Hopkins Bloomberg School of Public Health has secured a National Institutes of Health R01 grant to conduct a five-year study into the long-term health and economic outcomes of GLP-1 receptor agonists, including semaglutide and tirzepatide. The grant is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and will draw on Truveta Data linked with de-identified health insurance claims covering more than 140 million patients across the United States.
The study is led by principal investigator Joseph Levy, an assistant professor in the Department of Health Policy and Management at Johns Hopkins, working alongside researchers at Duke University. It builds on work already under way through the Truveta User Community at the Hopkins Business of Health Initiative, which was established under the leadership of Daniel Polsky, a Bloomberg Distinguished Professor with joint appointments at the Bloomberg School of Public Health and the Johns Hopkins Carey Business School.
What the research will examine
The central focus is not whether GLP-1 therapies work clinically, but whether patients can access them and what the evidence base looks like for those who stand to benefit most. Specifically, the team will assess which patient populations derive the greatest benefit, how GLP-1 treatment affects healthcare spending over time, and what data would need to be generated to justify broader coverage across Medicare, Medicaid, and commercial health plans.
GLP-1 medicines have moved well beyond their origins as diabetes treatments. Approved formulations of semaglutide and tirzepatide now carry indications for chronic weight management and cardiovascular risk reduction, and emerging research has pointed to potential utility in alcohol use disorder. That expanding clinical footprint has intensified the policy debate: as prescriptions have surged, so have insurer concerns about the cost burden, with list prices for branded GLP-1 therapies running to several hundred pounds or dollars per month without rebate.
Market and regulatory context
The GLP-1 market is among the most closely watched in pharmaceuticals, with Novo Nordisk and Eli Lilly currently dominant. A number of biosimilar developers and smaller-molecule entrants are working through earlier development stages, and policymakers in the US and UK have signalled increasing interest in value-based access frameworks that go beyond standard cost-effectiveness thresholds.
NIH R01 grants are awarded through a competitive peer-review process and represent the institute's core investigator-initiated research mechanism. Their award to a real-world evidence study of this kind reflects a broader shift in how health agencies are approaching evidence generation: moving from controlled trial settings toward large-scale claims and electronic health record data to answer population-level questions that randomised trials are poorly suited to address.
For Truveta, whose membership includes major US health systems such as Providence, Northwell Health, CommonSpirit Health, and Baylor Scott and White Health, the award provides a high-profile validation of its data infrastructure in an academically rigorous context. The company positions its platform as capable of supporting regulatory-grade evidence generation, and an NIH-funded longitudinal study using its data is consistent with that positioning.
The findings are expected to carry weight with payers and policymakers at a moment when coverage decisions for GLP-1 therapies remain unsettled. Medicare's coverage of semaglutide for obesity, for example, has been the subject of ongoing legislative debate, and the question of what level of real-world evidence is sufficient to unlock broader reimbursement is precisely what this study aims to address.